| Q1 | Q2 | Q3 | Q4 | P for trend |
---|---|---|---|---|---|
Increased WC | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 168 (8.5) | 154 (7.8) | 153 (7.7) | 126 (6.4) | 0.005 |
 Crude OR (95% CI) | 1.0 (ref) | 0.88 (0.68–1.15) | 0.87 (0.67–1.14) | 0.67 (0.51–0.88) | 0.004 |
 Multivariable OR (95% CI) | 1.0 (ref) | 0.79 (0.55–1.13) | 0.75 (0.52–1.07) | 0.60 (0.41–0.88) | 0.009 |
Elevated TG | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 176 (8.9) | 159 (8.0) | 144 (7.3) | 111 (5.6) | < 0.001 |
 Crude OR (95% CI) | 1.0 (ref) | 0.86 (0.66–1.12) | 0.75 (0.57–0.98) | 0.53 (0.40–0.69) | < 0.001 |
 Multivariable OR (95% CI) | 1.0 (ref) | 1.01 (0.75–1.37) | 0.82 (0.60–1.11) | 0.69 (0.50–0.96) | 0.012 |
Elevated BP | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 153 (7.7) | 138 (7.0) | 124 (6.3) | 118 (5.9) | 0.007 |
 Crude OR (95% CI) | 1.0 (ref) | 0.87 (0.66–1.14) | 0.75 (0.57–0.99) | 0.70 (0.53–0.93) | 0.009 |
 Multivariable OR (95% CI) | 1.0 (ref) | 1.00 (0.74–1.36) | 0.83 (0.61–1.14) | 0.96 (0.70–1.32) | 0.63 |
Elevated FBG | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 36 (1.8) | 43 (2.2) | 32 (1.6) | 26 (1.3) | 0.10 |
 Crude OR (95% CI) | 1.0 (ref) | 1.22 (0.77–1.93) | 0.88 (0.54–1.45) | 0.71 (0.42–1.19) | 0.10 |
 Multivariable OR (95% CI) | 1.0 (ref) | 1.35 (0.83–2.20) | 0.92 (0.54–1.55) | 0.78 (0.44–1.37) | 0.21 |
Reduced HDL-C | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 96 (4.8) | 109 (5.5) | 106 (5.3) | 115 (5.8) | 0.19 |
 Crude OR (95% CI) | 1.0 (ref) | 1.18 (0.87–1.61) | 1.14 (0.83–1.55) | 1.26 (0.93–1.71) | 0.18 |
 Multivariable OR (95% CI) | 1.0 (ref) | 1.02 (0.74–1.40) | 0.92 (0.67–1.27) | 0.96 (0.70–1.33) | 0.72 |
MetS | Â | Â | Â | Â | Â |
 Prevalence, n (%) | 80 (4.0) | 90 (4.5) | 73 (3.7) | 59 (3.0) | 0.025 |
 Crude OR (95% CI) | 1.0 (ref) | 1.16 (0.83–1.61) | 0.90 (0.64–1.27) | 0.70 (0.49–1.01) | 0.022 |
 Multivariable OR (95% CI) | 1.0 (ref) | 1.32 (0.90–1.92) | 0.90 (0.61–1.33) | 0.81 (0.53–1.24) | 0.14 |